X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1427) 1427
Book Chapter (25) 25
Dissertation (23) 23
Magazine Article (3) 3
Conference Proceeding (1) 1
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fibrates (974) 974
humans (659) 659
statins (466) 466
fibrate (369) 369
male (302) 302
pharmacology & pharmacy (260) 260
animals (251) 251
hypolipidemic agents - therapeutic use (235) 235
cholesterol (222) 222
female (219) 219
middle aged (193) 193
coronary-heart-disease (192) 192
atherosclerosis (173) 173
dyslipidemia (165) 165
risk factors (164) 164
triglycerides (164) 164
lipids (160) 160
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (156) 156
statin (152) 152
cardiac & cardiovascular systems (146) 146
fenofibrate (144) 144
hypolipidemic agents - pharmacology (138) 138
niacin (138) 138
biochemistry & molecular biology (137) 137
metabolic syndrome (130) 130
ezetimibe (128) 128
gemfibrozil (127) 127
aged (121) 121
diabetes (118) 118
peripheral vascular disease (117) 117
dyslipidemias - drug therapy (115) 115
adult (110) 110
endocrinology & metabolism (109) 109
cardiovascular disease (108) 108
drug therapy, combination (108) 108
treatment outcome (99) 99
triglycerides - blood (95) 95
mice (92) 92
risk (91) 91
ppar-alpha (90) 90
secondary prevention (90) 90
fenofibrate - pharmacology (89) 89
fenofibrate - therapeutic use (89) 89
cardiovascular diseases - prevention & control (88) 88
cardiovascular-disease (84) 84
type-2 diabetes-mellitus (84) 84
cholesterol, hdl - blood (83) 83
hypolipidemic agents - adverse effects (83) 83
hyperlipidemias - drug therapy (80) 80
density-lipoprotein cholesterol (79) 79
metabolism (79) 79
therapy (78) 78
inflammation (77) 77
hypertriglyceridemia (76) 76
myocardial-infarction (76) 76
prevention (76) 76
atorvastatin (74) 74
expression (73) 73
cardiovascular diseases (72) 72
type 2 diabetes (72) 72
medicine, general & internal (71) 71
cholesterol, ldl - blood (70) 70
fibric acids (70) 70
rats (70) 70
fibric acids - therapeutic use (69) 69
lipoproteins (68) 68
simvastatin (68) 68
hyperlipidemia (67) 67
cardiovascular risk (66) 66
c-reactive protein (65) 65
nicotinic acid (64) 64
ppar (64) 64
risk-factors (64) 64
low density lipoproteins (63) 63
bezafibrate (62) 62
insulin resistance (62) 62
insulin-resistance (62) 62
lipids - blood (61) 61
anticholesteremic agents - therapeutic use (60) 60
high-density-lipoprotein (60) 60
liver (60) 60
clofibric acid - therapeutic use (59) 59
coronary heart disease (58) 58
gene-expression (58) 58
medicine & public health (58) 58
rhabdomyolysis (58) 58
hypercholesterolemia (57) 57
review (57) 57
cardiovascular (53) 53
diabetes mellitus, type 2 - drug therapy (53) 53
low-density-lipoprotein (53) 53
coronary-artery-disease (52) 52
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (52) 52
triglyceride (52) 52
hdl-cholesterol (51) 51
ppar alpha - agonists (51) 51
research (51) 51
diabetes mellitus (50) 50
disease (49) 49
fatty acids (49) 49
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1240) 1240
French (112) 112
Czech (38) 38
German (31) 31
Spanish (29) 29
Portuguese (17) 17
Polish (16) 16
Japanese (12) 12
Hungarian (4) 4
Russian (4) 4
Korean (3) 3
Slovak (3) 3
Slovenian (2) 2
Chinese (1) 1
Croatian (1) 1
Italian (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 11/2012, Volume 60, Issue 20, pp. 2061 - 2071
Journal Article
Annals of medicine (Helsinki), ISSN 1365-2060, 2018, Volume 50, Issue 6, pp. 461 - 484
Inflammatory changes are responsible for maintenance of the atherosclerotic process and may underlie some of the most feared vascular complications. Among the... 
CRP | fibrates | PCSK9 | statin | LDL-C | Ezetimibe | C-REACTIVE PROTEIN | METABOLIC SYNDROME | ESTER TRANSFER PROTEIN | TRIGLYCERIDE-RICH LIPOPROTEINS | ACUTE CORONARY SYNDROMES | DENSITY-LIPOPROTEIN-CHOLESTEROL | ENDOTHELIAL FUNCTION | MEDICINE, GENERAL & INTERNAL | ATP-CITRATE LYASE | VASCULAR INFLAMMATION | LONG-TERM EFFICACY
Journal Article
Biochimica et biophysica acta. Molecular and cell biology of lipids, ISSN 1388-1981, 2007, Volume 1771, Issue 8, pp. 1065 - 1081
Journal Article
Cardiovascular diabetology, ISSN 1475-2840, 2012, Volume 11, Issue 1, pp. 140 - 140
All fibrates are peroxisome proliferators-activated receptors (PPARs)-alpha agonists with ability to decrease triglyceride and increase high density... 
Combined fibrate/statin therapy | Prevention | Type 2 diabetes | Atherogenic dyslipidemia | Bezafibrate | PPAR | Residual cardiovascular risk | Metabolic syndrome | PEROXISOME-PROLIFERATOR | CARDIAC & CARDIOVASCULAR SYSTEMS | CARDIOVASCULAR OUTCOMES | SECONDARY PREVENTION | BETA-CELL FUNCTION | SYSTEMIC INFLAMMATION | RANDOMIZED CONTROLLED TRIAL | HEART-DISEASE | INSULIN-RESISTANCE | ENDOCRINOLOGY & METABOLISM | CORONARY-ARTERY-DISEASE | Cardiovascular Diseases - prevention & control | Glycated Hemoglobin A - metabolism | Humans | Diabetes Mellitus, Type 2 - epidemiology | Dyslipidemias - blood | Lipids - blood | Cardiovascular Diseases - epidemiology | Drug Therapy, Combination | Peroxisome Proliferator-Activated Receptors - agonists | Bezafibrate - therapeutic use | Hypolipidemic Agents - adverse effects | Dyslipidemias - drug therapy | Risk Assessment | Risk Factors | Diabetes Mellitus, Type 2 - prevention & control | Insulin Resistance | Treatment Outcome | Biomarkers - blood | Bezafibrate - adverse effects | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Animals | Dyslipidemias - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Peroxisome Proliferator-Activated Receptors - metabolism | Hypolipidemic Agents - therapeutic use | Blood Glucose - metabolism | Cardiovascular disease | Insulin resistance | Diabetes | Diet | Cholesterol
Journal Article
Results in Chemistry, ISSN 2211-7156, 01/2020, Volume 2, p. 100018
Synthetic routes for the preparation of (i) isopropyl 2-(4-(4-chlorobenzyl)phenoxy)-2-methyl propanoate (Reduced Fenofibrate, Fibrane) (2) from isopropyl... 
Fibrate | Fibrane
Journal Article